Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
about
Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signalingRapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers
P2860
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@en
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@nl
type
label
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@en
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@nl
prefLabel
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@en
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@nl
P2093
P2860
P1476
Pharmacologic inhibition of mT ...... in non-small cell lung cancer.
@en
P2093
Boyka Markova
Frank Breitenbuecher
Martin Schuler
Patricia S Hähnel
Stefan Kasper
Stephan Herbertz
P2860
P2888
P304
P356
10.1007/S00432-011-1123-9
P577
2011-12-28T00:00:00Z